Investorideas.com  big ideas for global investors Search www.investorideas.com
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   




Investor Ideas Snapshot: NASDAQ Top Percentage Gainers; (SVA), (CWTR), (SIGM), (AFFY)

Category: Investment

Ideas get bigger when you share them...

Visit: Sinovac Biotech Ltd.

March 14, 2013 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors reports on the top percentage gainers on the NASDAQ for March 14th, 2013.

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

Sinovac Biotech Ltd., (NASDAQ:SVA) trading at $4.19 gained $1.00 or 31.41% on a high volume of 7,128,371 shares, making it today's top percentage gainer on the NASDAQ.

Sinovac Biotech Ltd. said earlier today that its experimental vaccine for hand, foot and mouth disease met its goal in a late-stage clinical trial.

The company said its vaccine EV71 was 95.4 percent effective in stopping infection caused by one strain of the virus in children between 6 and 35 months old. Serious side effects occurred in 2.2 percent of patients, a rate that was similar to placebo. Most of the side effects were not considered vaccine-related.

Hand, foot and mouth disease is common, especially in children under the age of five. The illness typically brings a low fever, rash, and sores on the hands, feet and mouth. China sees deadly outbreaks of the disease every spring and summer, particularly in rural areas where hygiene is poor. Sinovac said more than 1 million cases have been identified over the last five years, and over that time 500 to 900 people have died of the disease each year.

Around 10,000 children were enrolled in the trial in early 2012, before the start of the epidemic season. They received two shots four weeks apart.

Coldwater Creek Inc., (NASDAQ:CWTR) trading at $3.74 moved up $0.53 or 16.51% on a volume of 306,234 shares.

Coldwater Creek Inc., though they had a loss, beat Wall Street's expectations as well as the revenue expectation. The revenue win is a positive sign to shareholders seeking high growth out of the company.

Adjusted earnings per share increased to $-0.65 in the quarter versus EPS of $-0.76 in the year-earlier quarter, while revenue decreased 1.63% to $220.7 million from the year-earlier quarter, still beating the average revenue estimate of $218.76 million.

Sigma Designs Inc., (NASDAQ:SIGM) trading at $5.08 rose $0.66 or 14.82% on a volume of 496,796 shares.

Sigma Designs, Inc. recently reported a loss that missed Wall Street's expectations, but managed to rise above the revenue expectation.

Adjusted earnings per share decreased to $-0.54 in the quarter versus EPS of $-0.43 in the year-earlier quarter, while revenue rose 24.26% to $44.2 million from the year-earlier quarter. Sigma Designs, Inc. reported adjusted EPS loss of $0.54 per share which missed the mean analyst estimate of $-0.25.

Affymax Inc., (NASDAQ:AFFY) trading at $3.27 gained $0.36 or 12.37% on a high volume of 9,067,051 shares.

Law Offices of Howard G. Smith announces yesterday that it is investigating potential claims against Affymax, Inc. concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by Affymax between December 8, 2011 and January 2, 2013 were false and misleading regarding the Company's business and financial prospects.

Affymax is a biopharmaceutical company engaged in the development of drugs for the treatment of serious and life-threatening conditions in the United States. The investigation is related to a February 23, 2013 joint announcement, issued by Affymax and Japan-based Takeda Pharmaceutical Company Limited, of a nationwide voluntary recall of OMONTYS Injection. OMONTYS Injection is a treatment for anemia due to chronic kidney disease in adult patients on dialysis. According to the Company, the recall is related to "new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal." Affymax has a strategic alliance agreement with Takeda to develop and commercialize OMONTYS.

About NASDAQ

http://www.nasdaq.com/

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for the free investor news and stock alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Or …

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors

http://www.investorideas.com/membership/

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com


Free News Alerts
Email:  





TOP

Investor Ideas © 2000 - 2014 InvestorIdeas.com®, ECON

Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |